Sattva Sukun Lifecare promoter Roshan Dealmark Private Limited disposed of 18,00,000 equity shares through an on-market transaction on September 11, 2026. The sale reduces the promoter group’s aggregate holding in the company.

The disposal was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The target company, now known as Tavexia Lifecare Limited, is listed on the Bombay Stock Exchange.

Shareholding Changes

Prior to the transaction, Roshan Dealmark held 2,16,49,777 shares, while its Person Acting in Concert (PAC), Puja Agarwal, held 80,000 shares. The combined promoter group holding stood at 2,17,29,777 shares, representing 5.66% of the total diluted share capital.

Following the sale of 18,00,000 shares by Roshan Dealmark, the entity’s individual holding dropped to 1,98,49,777 shares. Puja Agarwal’s holding remained unchanged at 80,000 shares. The total promoter group stake decreased by 0.47 percentage points to 5.19%.

What the Numbers Show

The paid-up capital of Tavexia Lifecare Limited remained constant at ₹38,36,01,248 (38,36,01,248 shares of ₹1 each) before and after the transaction. This indicates the sale was a secondary market transfer between existing shareholders and investors, rather than a fresh issuance or buyback affecting the company’s equity base. The reduction in promoter stake from 5.66% to 5.19% reflects a partial exit or portfolio adjustment by the promoter group without altering the company’s capital structure.

Tavexia Lifecare Limited has scheduled its 46th Annual General Meeting (AGM) for Wednesday, September 30, 2026, at 12:00 pm via Video Conferencing. The company has published the AGM notice in compliance with SEBI LODR Regulation 30, confirming the agenda includes adoption of FY25-26 accounts and special business items.

The meeting will address ordinary business including the adoption of FY25-26 accounts and special business involving auditor appointments and related-party transactions. The board previously announced plans to acquire up to a 60% stake in Meyonex Pharmaceuticals Limited. This acquisition proposal was approved during the board meeting on September 7, 2026.

Auditor and Board Changes

Tavexia accepted the resignation of its statutory auditors, M/s SSRV & Associates, effective September 7, 2026. The board appointed M/s DEVAM & Associates LLP as the new statutory auditors for a five-year term from FY27 to FY31, subject to shareholder approval at the upcoming AGM.

Additionally, the board recommended the reappointment of Mrs. Khushboo Vasudev as an independent director for a second five-year term starting December 31, 2026. This appointment also requires shareholder approval.

Related-Party Transaction Limits

The board seeks shareholder approval for material related-party transactions under Section 188 of the Companies Act, 2013. The proposed limit is up to ₹100 crore per related party for transactions including sale/purchase of goods, services, lending, and investments. This cap applies for an 18-month period from April 1, 2026, to September 30, 2027.

Key related parties include:

• Roshan Dealmark Private Limited (Promoter Company)
• Mayukh Trading Private Limited (Subsidiary Company)
• Mit Tarunkumar Brahmabhatt (Managing Director) and his relatives/entities

Key Financials of Target Entity

Corporate Governance Updates

The board took on record the secretarial audit report for FY25-26 from M/s Brajesh Gupta & Co. It also approved the Board Report, Corporate Governance Report, and Management Discussion and Analysis for the financial year ended March 31, 2026.

Mr. Brajesh Gupta was appointed as the scrutinizer for the e-voting process for the 46th AGM. The book closure period remains fixed from September 24, 2026, to September 30, 2026.